ValiRx plc (VAL.L) LSE
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
ValiRx plc
Address
Stonebridge House
Hatfield, CM22 7BD
United Kingdom of Great Britain and Northern Ireland (the)
Phone
442030084416
Website
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
January 07, 2002
Key Executives
| Name | Title | Pay | Year Born |
| Mark Eccleston | Chief Executive Officer, Director, Member of Scientific & Commercial Advisory Board | 83,381 | 1971 |
| James Gerry Desler | Chief Financial Officer, Company Secretary & Executive Director | 66,450 | 1945 |
| Andrew Carnegie | Head of Strategic Commercial Development | 0 | N/A |
| Mark Treharne | Corporate Development Manager | 0 | N/A |
| Kumar Nawani | Head of Operations | 0 | N/A |
Description
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to treat prostate cancer and other hormone-dependent solid tumors, including breast and ovarian cancer. Another key candidate, VAL401, a reimagined version of the antipsychotic drug risperidone, has successfully completed Phase II clinical trials for addressing non-small cell lung cancer. The company's pipeline also features VAL301, a peptide currently in pre-clinical development for treating endometriosis in women. Additionally, BC201, a compound combining the peptide ingredient from VAL201/VAL301 with complementary active components, is being developed to alleviate severe symptoms of COVID-19. ValiRx plc was established in 2000 and is headquartered in Hatfield, United Kingdom.
